ACTRN12624000155594
Recruiting
未知
ProspEctive comparison of Prostate Specific Membrane Antigen (PSMA) PET CT vs Fludeoxyglucose (FDG) PET CT in staging of Renal Tumours (PEPPER): a pilot trial.
Metro North HHS0 sites30 target enrollmentFebruary 16, 2024
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Renal tumours
- Sponsor
- Metro North HHS
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged 18 years or older
- •Renal tumours \>7cm, or cT3/4 and/or cN1 or equivocal retroperitoneal lymph node involvement on CT
- •M0 or equivocal on CT chest, abdomen, pelvis within 6 weeks prior to recruitment
- •Able to provide informed consent
- •Willing and able to comply with study protocol ; Aged 18 years or older
- •Renal tumours \>7cm, or cT3/4 and/or cN1 or equivocal retroperitoneal lymph node involvement on CT
- •M0 or equivocal on CT chest, abdomen, pelvis within 6 weeks prior to recruitment
- •Able to provide informed consent
- •Willing and able to comply with study protocol
Exclusion Criteria
- •History of other active malignancy within last 2 years, excluding non\-melanoma cutaneous neoplasms
- •Renal tumours having an atypical appearance where an alternative diagnosis is felt to be more likely eg urothelial carcinoma
- •PSMA or FDG PET in the preceding 2 years.
- •Significant co\-morbidity or other barrier to completing study processes
- •Patients with renal masses with IVC tumour thrombus if awaiting PET scans will cause unnecessary surgical delay
- •Pregnancy, or planning pregnancy in the next 6 months. ; History of other active malignancy within last 2 years, excluding non\-melanoma cutaneous neoplasms
- •Renal tumours having an atypical appearance where an alternative diagnosis is felt to be more likely eg urothelial carcinoma
- •PSMA or FDG PET in the preceding 2 years.
- •Significant co\-morbidity or other barrier to completing study processes
- •Patients with renal masses with IVC tumour thrombus if awaiting PET scans will cause unnecessary surgical delay
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Diagnostic Performance of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Pre-operative Lymph Node Assessment in Intermediate and High-risk Nonmetastasic Prostate Cancer2024-516319-25-00Centre Hospitalier Regional Et Universitaire De Brest159
Terminated
Not Applicable
The use of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans and Magnetic Resonance Imaging (MRI) to better guide high dose radiotherapy for men with high-risk prostate cancer as a means to improve clinical and quality of life outcomes.High risk prostate cancerACTRN12617000816358The Garvan Institute of Medical Research20
Recruiting
Phase 2
Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstructiometastatic castration-resistant prostate cancerCancer - ProstateACTRN12621000611820St Vincent's Hospital, Sydney22
Not yet recruiting
Not Applicable
Prostate-specific Membrane Antigen (PSMA) expression in cervical carcinomaC53.9Cervix uteri, unspecifiedDRKS00023289niversitätsklinikum FreiburgKlinik für Frauenheilkunde100
Completed
Not Applicable
Prostate-specific Membrane Antigen (PSMA) expression in endometrial cancerC54Malignant neoplasm of corpus uteriDRKS00025005niversitätsklinikum Freiburg Klinik für Frauenheilkunde61